Hunan Hansen Pharmaceutical Co Ltd (002412) - Total Liabilities
Based on the latest financial reports, Hunan Hansen Pharmaceutical Co Ltd (002412) has total liabilities worth CN¥310.49 Million CNY (≈ $45.43 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Hunan Hansen Pharmaceutical Co Ltd to see how much of total assets are deployed in long-term investments.
Hunan Hansen Pharmaceutical Co Ltd - Total Liabilities Trend (2006–2025)
This chart illustrates how Hunan Hansen Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Hunan Hansen Pharmaceutical Co Ltd.
Hunan Hansen Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Hunan Hansen Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Jasan Holding Group Co Ltd
SHG:603558
|
China | CN¥1.57 Billion |
|
Patria Investments Ltd
NASDAQ:PAX
|
USA | $1.11 Billion |
|
Aura Biosciences Inc
NASDAQ:AURA
|
USA | $30.43 Million |
|
Sincere Navigation Corp
TW:2605
|
Taiwan | NT$4.54 Billion |
|
Calian Technologies Ltd
TO:CGY
|
Canada | CA$428.52 Million |
|
QITIAN Technology Group Co Ltd
SHE:300061
|
China | CN¥684.65 Million |
|
Credit Corp Group Ltd
AU:CCP
|
Australia | AU$507.87 Million |
|
Empire State Realty Trust Inc
NYSE:ESRT
|
USA | $2.31 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down Hunan Hansen Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Hunan Hansen Pharmaceutical Co Ltd's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hunan Hansen Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hunan Hansen Pharmaceutical Co Ltd (2006–2025)
The table below shows the annual total liabilities of Hunan Hansen Pharmaceutical Co Ltd from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥312.15 Million ≈ $45.68 Million |
-9.22% |
| 2024-12-31 | CN¥343.85 Million ≈ $50.32 Million |
-7.93% |
| 2023-12-31 | CN¥373.46 Million ≈ $54.65 Million |
-5.89% |
| 2022-12-31 | CN¥396.81 Million ≈ $58.07 Million |
+7.54% |
| 2021-12-31 | CN¥368.99 Million ≈ $53.99 Million |
+25.54% |
| 2020-12-31 | CN¥293.92 Million ≈ $43.01 Million |
-16.72% |
| 2019-12-31 | CN¥352.93 Million ≈ $51.64 Million |
-18.87% |
| 2018-12-31 | CN¥435.02 Million ≈ $63.66 Million |
-9.59% |
| 2017-12-31 | CN¥481.18 Million ≈ $70.41 Million |
+15.70% |
| 2016-12-31 | CN¥415.88 Million ≈ $60.86 Million |
+227.90% |
| 2015-12-31 | CN¥126.83 Million ≈ $18.56 Million |
-40.89% |
| 2014-12-31 | CN¥214.59 Million ≈ $31.40 Million |
+0.06% |
| 2013-12-31 | CN¥214.46 Million ≈ $31.38 Million |
+179.39% |
| 2012-12-31 | CN¥76.76 Million ≈ $11.23 Million |
+39.70% |
| 2011-12-31 | CN¥54.95 Million ≈ $8.04 Million |
+11.61% |
| 2010-12-31 | CN¥49.23 Million ≈ $7.20 Million |
-27.27% |
| 2009-12-31 | CN¥67.69 Million ≈ $9.90 Million |
-20.06% |
| 2008-12-31 | CN¥84.67 Million ≈ $12.39 Million |
-2.11% |
| 2007-12-31 | CN¥86.49 Million ≈ $12.66 Million |
-40.13% |
| 2006-12-31 | CN¥144.46 Million ≈ $21.14 Million |
-- |
About Hunan Hansen Pharmaceutical Co Ltd
Hunan Hansen Pharmaceutical Co., Ltd. engages in the production and sale of traditional Chinese preparations in China and internationally. The company offers medications for digestive, cardiovascular, cerebrovascular, and urological diseases, as well as for traumatology and diagnostic applications. It provides its products in various forms, including injections, mixtures, tablets, capsules, granu… Read more